首页> 外文期刊>EuroIntervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology >Intracoronary versus intravenous bolus abciximab administration in patients undergoing primary percutaneous coronary intervention with acute ST-elevation myocardial infarction: a pooled analysis of individual patient data from five randomised controlled trials
【24h】

Intracoronary versus intravenous bolus abciximab administration in patients undergoing primary percutaneous coronary intervention with acute ST-elevation myocardial infarction: a pooled analysis of individual patient data from five randomised controlled trials

机译:初次经皮冠状动脉介入治疗并急性ST段抬高型心肌梗死的患者进行冠脉内或静脉推注abciximab给药:来自五项随机对照试验的个体患者数据汇总分析

获取原文
获取原文并翻译 | 示例
           

摘要

Aims: In recent years, intracoronary bolus abciximab has emerged as an alternative to the standard intravenous route in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). The aim of the current study was to perform an individual patient-level pooled analysis of randomised trials, comparing intracoronary versus intravenous abciximab bolus use in STEMI patients undergoing primary PCI.
机译:目的:近年来,在接受原发性经皮冠状动脉介入治疗(PCI)的ST抬高型心肌梗死(STEMI)患者中,冠脉内推注abciximab替代了标准的静脉内途径。本研究的目的是对随机试验进行个体患者水平的汇总分析,比较接受原发性PCI的STEMI患者冠状动脉内和静脉内阿昔单抗推注使用情况。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号